Category Archives: News
THE OPIOID EPIDEMIC: ASSESSING OUTCOMES OF OPIOID ABUSE IN CHRONIC INFLAMMATORY DISEASE (ULCERATIVE COLITIS VS CROHN’S DISEASE)
The use of Opiates in patients with Inflammatory Bowel Disease (IBD) has been studied previously. However, to our knowledge, no studies have compared outcomes between patients with opioid abuse with ulcerative colitis (UC) versus patients with opioid a… Continue reading
DECREASED EXPRESSION OF NHE3 IN COLON CANCER EPITHELIUM IS ASSOCIATED WITH DNA DAMAGE, INCREASED LOCAL INFLAMMATION AND TUMOR GROWTH
Dysregulation of intracellular and extracellular pH in cancer is thought to contribute to extracellular matrix remodeling, cancer metastasis, and favors cell migration and proliferation. Although the primary attention has been focused on the role of th… Continue reading
PLIN2 IS AN ARYL HYDROCARBON RECEPTOR TRANSCRIPTIONAL TARGET AND MAY CONTRIBUTE TO MUCOSAL RESTITUTION
Dysregulated barrier function contributes to the pathogenesis in inflammatory bowel diseases (Crohn’s (CD) and ulcerative colitis (UC)). The cytosolic transcription factor aryl hydrocarbon receptor (AHR) is activated by both endogenous and exogenous li… Continue reading
INTERLEUKIN 21-INDUCED METABOLIC REPROGRAMMING DRIVES CD4 T CELL INFLAMMATORY RESPONSE DURING INTESTINAL INFLAMMATION
Significant proportion of inflammatory bowel disease (IBD) patients continue to respond inconsistently to therapies, underscoring disease complexity and the need for efficacious treatment. Interleukin 21 (IL-21), which is known to support T helper (Th)… Continue reading
ACTIVATION OF MK2 IN CROHN’S DISEASE-ASSOCIATED FIBROSIS: NEW TARGET FOR ANTI-FIBROTIC THERAPY
Fibrosis is the major aggressive complication of Crohn’s disease (CD), causing intestinal obstruction. No targeted therapies are currently available to revert CD-associated fibrosis. While inflammatory mechanisms in CD have been extensively investigate… Continue reading
SELECTION OF MICROBIOME-DERIVED PEPTIDES THROUGH MULTI-TECHNOLOGY META-ANALYSIS, BINDING, AND FUNCTIONAL ASSAYS, IDENTIFIES PEPTIDES WITH THERAPEUTIC POTENTIAL THAT MODULATE IMMUNE RESPONSES AND DISEASE
Microbiome-driven drug discovery holds great promise for therapeutic development. However, identification of disease-associated microbiome-host interactions are challenging, owing largely to the complexity of a diverse community and the myriad of direc… Continue reading
TRENDS IN ADMISSIONS, OUTCOMES AND FINANCIAL BURDEN OF C. DIFFICILE INFECTION RELATED HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS: A NATIONWIDE ANALYSIS
Inflammatory bowel disease (IBD) patients with colonic involvement are known to have microbiome changes which may increase their risk of C. difficile infection (CDI). We conducted an analysis to describe the implications of CDI on hospitalized IBD pati… Continue reading
OUTCOMES OF TOTAL PROCTOCOLECTOMY (TPC) WITH ILEAL POUCH ANAL ANASTOMOSIS (IPAA)
Total proctocolectomy (TPC) followed by ileal pouch anal anastomosis (IPAA) is the surgery of choice for eligible ulcerative colitis patients who are refractory to medical therapy or develop complications such as adenocarcinoma or dysplasia. Although a… Continue reading
ENHANCED RECOVERY PROGRAMS: HOW ARE WE BENEFITTING PATIENTS WITH IBD?
Enhanced Recovery Programs (ERPs) improve postoperative outcomes in colorectal surgery. Patients with IBD have been shown to benefit from use of ERP, but are immunosuppressed and chronically ill. We aimed to determine how patient outcomes under an ERP … Continue reading
ACUITY OF PEDIATRIC INFLAMMATORY BOWEL DISEASE ADMISSIONS PRE AND DURING THE COVID-19 PANDEMIC
The COVID19 pandemic has introduced new challenges to the diagnosis and management of pediatric Inflammatory Bowel Disease (IBD). Many patients have had limited access to their providers through telemedicine and may choose to delay non-emergent treatme… Continue reading